Search the Newsreel

Adagio Medical Holdings Inc|Price:0.482|Chg%:-0.008

Adagio Medical Holdings Inc (ADGM) has strong fundamentals and high growth potential, despite a recent weak stock market performance. Its valuation is considered fairly priced, with institutional ownership being very high. Analysts have rated it as a Buy, with a target price suggesting a …

Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Agios Pharmaceuticals Inc. (AGIO) stock, indicating a current price of $36.97 with a 1.68% increase. It also includes information on average analyst price targets (currently unavailable) and earnings (no information). The page, hosted on Timothy Sykes' …

Adagio Medical Holdings Inc (ADGM) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Adagio Medical Holdings Inc's (ADGM) financial health, ranking it 143 out of 200 in the Healthcare Equipment & Supplies industry with a current financial score of 6.66. While its financial status is robust, the operating efficiency is low. …

TradingKey

This article provides a detailed quarterly income statement for Adagio Medical Holdings Inc (ADGM) from FY2021Q4 to FY2026Q1, including key financial metrics like total revenue, operating expenses, net income, and basic/diluted earnings per share. It also includes FAQs explaining how to interpret income statements …

Adagio Medical Holdings Inc (ADGM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article assesses the risk profile of Adagio Medical Holdings Inc (ADGM), noting its current risk score of 1.46, placing it 182nd out of 200 in the Healthcare Equipment & Supplies industry. The company's beta of -0.18 indicates it tends to underperform in bull …

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN)

Analysts from Goldman Sachs and Maxim Group have issued reports on Agios Pharma (AGIO) and Imunon (IMNN), respectively, within the Healthcare sector. Goldman Sachs maintained a Hold rating on Agios Pharma with a $32.00 price target, while Maxim Group maintained a Buy rating on …

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios Pharmaceuticals (AGIO) is projected to report a year-over-year increase in earnings and 82.2% higher revenues for Q2 2026, with an expected quarterly loss of $1.86 per share. The company has a Zacks Earnings ESP of +12.67% and a Zacks Rank #3, suggesting a …

Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Drug Tebapivat

Agios Pharmaceuticals (AGIO) has halted the development of its sickle cell drug, tebapivat, after it failed to show significant differentiation from a placebo in a phase 2 trial, leading to an initial stock drop. Despite this setback, the company maintains a stable financial position …

AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program

Agios Pharmaceuticals (AGIO) announced the discontinuation of its tebapivat sickle cell disease (SCD) program after Phase II data failed to show sufficient clinical differentiation from other PK activators, causing its shares to drop nearly 7%. This decision affects all indications for tebapivat, with Agios …

Agios Abandons Tebapivat in Sickle Cell Disease

Agios Pharmaceuticals announced it is discontinuing the development of its oral pyruvate kinase activator, tebapivat, for sickle cell disease, despite meeting its primary endpoint in a Phase II trial. The company concluded that the results lacked sufficient differentiation from its lead candidate, mitapivat, which …

H.C. Wainwright lowers Agios Pharma price target to $52 on trial data

H.C. Wainwright has lowered its price target for Agios Pharmaceuticals (NASDAQ:AGIO) to $52 from $54 due to Phase 2 trial results for tebapivat in sickle cell disease not showing sufficient differentiation compared to mitapivat. Despite this setback, Agios will discontinue tebapivat development for sickle …

Agios Pharmaceuticals (AGIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article provides an overview of Agios Pharmaceuticals' (AGIO) FDA approvals, PDUFA dates, and drug alerts through 2026, focusing on their pipeline drugs: tebapivat, mitapivat, and AG-946. It details regulatory milestones, clinical trial results, and FDA designations for these therapies, which are primarily aimed …

Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint

Agios Pharmaceuticals has discontinued the development of tebapivat, a sickle cell disease drug, after Phase 2 clinical data showed it lacked sufficient differentiation compared to other drugs in its class, including Agios's own Pyrukynd. While tebapivat showed some improvement, its response was not dose-dependent …

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development

Agios Pharmaceuticals (NASDAQ: AGIO) has decided to discontinue the development of tebapivat for sickle cell disease after Phase 2 trial results, despite showing improvements in hemoglobin levels, did not demonstrate sufficient clinical differentiation from other therapies. The company's stock is trading lower following this …

Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ)

Agios Pharmaceuticals (AGIO) announced it would cease development of its sickle cell disease drug tebapivat. This decision comes after the candidate failed to show sufficient differentiation from a placebo across three tested doses in a phase 2 trial, leading to an initial ~11% drop …

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals (AGIO) saw its stock tumble after discontinuing the development of its next-generation sickle cell drug, tebapivat, following a failed Phase 2 study. The company stated the drug did not sufficiently differentiate itself from other treatments in its class. This move threatens a …

Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)

Agios Pharmaceuticals' shares dropped after the company announced it would discontinue its sickle cell disease program for tebapivat. The decision followed a Phase 2 trial that did not show sufficiently differentiated results to warrant further development. Agios will now focus on mitapivat, another pyruvate …

Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Results

Agios Pharmaceuticals Inc (AGIO) experienced a 13% stock drop following the release of disappointing topline results from its tebapivat clinical trial. Despite strong financial strength, the company faces profitability challenges and a net selling trend from insiders. This decline highlights the speculative nature of …

Agios Pharmaceuticals stock falls on trial update By Investing.com

Agios Pharmaceuticals' shares fell 14% after the company announced it would discontinue development of tebapivat for sickle cell disease due to insufficient differentiation in Phase 2 trial results. While improvements in hemoglobin levels were observed, they did not meet Agios's criteria for advancing the …

Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance

Agios Pharmaceuticals announced topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin response rates of 43.8% (2.5 mg), 47.1% (5.0 mg), and 29.4% (7.5 mg) compared to 33.3% for placebo. Despite positive response rates, the company decided not to advance tebapivat's …

Adagio Medical Holdings, Inc. Interest Coverage (ADGM)

This article provides an analysis of Adagio Medical Holdings, Inc.'s interest coverage ratio. The company's interest coverage was -7.5x in FY2025 and -6.5x on a trailing-twelve-month basis as of Q1 FY26, indicating that its operating income does not cover its interest expenses. The data …

The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell

Agios Pharmaceuticals received FDA Priority Review for its drug mitapivat in sickle cell disease, with a PDUFA date of November 1, 2026. This potential approval could expand mitapivat's use beyond its current applications in PK deficiency and thalassemia, significantly impacting Agios's investment narrative and …

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

Agios Pharmaceuticals' stock is under scrutiny after its mitapivat drug for sickle cell disease received Priority Review from the FDA, leading to a significant 35.51% increase in its share price over 30 days. While analysts' "fair value" suggests the stock is still undervalued at …

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?

AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism

Imagion Biosystems Updates Director Share and Option Allocation in Placement Subject to Shareholder Vote on 10 August 2026

Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum

Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile?

Agios (AGIO) Q2 2025 Earnings Call Transcript

Leerink reiterates Agios Pharma stock rating amid rival drug data

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record

Insights: Imagion Biosystems Ltd (ASX:IBX)

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

Imagion Biosystems Gains FDA Fast-Track Approval for MagSense HER2 Breast Cancer Imaging Agent